Rilpivirine as a Treatment for HIV-infected Antiretroviral-naïve Adolescents: Week 48 Safety, Efficacy, Virology and Pharmacokinetics

Background: Rilpivirine 25 mg qd yields similar exposure in adolescents and adults (Pediatric study in Adolescents Investigating a New NNRTI TMC278 [PAINT] Cohort 1, Part 1). We report rilpivirine safety, efficacy, virology and pharmacokinetics in adolescents during 48 weeks of treatment (Cohort 1, Part 2). Methods: PAINT (NCT00799864) is a phase II, ongoing, open-label, single-arm trial of rilpivirine plus 2 investigator-selected nucleoside/nucleotide reverse-transcriptase inhibitors. Cohort 1 of PAINT includes treatment-naïve HIV-1-infected adolescents (≥12 to <18 years). Following approval in adults and after Part 1a in Cohort 1, enrollment was restricted to screening viral load (VL) ⩽100,000 copies/mL. Results: Overall, 20 (56%) of 36 patients were women, 18 (50%) were aged ≥12 to <15 years, 32 (89%) were Black or African American, mostly from South Africa or Uganda, and 28 (78%) had baseline VL ⩽100,000 copies/mL. At week 48, adverse events considered possibly related to treatment occurred in 13 (36%) patients, mostly (excluding investigations) somnolence (n = 5, 14%) and nausea (n = 2, 6%). Most adverse events were grade 1 or 2, and 7 (19%) patients had grade 3 or 4 adverse events. Week 48 virologic response (VL <50 copies/mL, time-to-loss-of-virologic-response) was achieved in 26 of the 36 (72%) patients: 22 of the 28 (79%) with baseline VL ⩽100,000 copies/mL and 4 of the 8 (50%) with baseline VL >100,000 copies/mL. Median (range) CD4+ count increased by 184 (−135 to 740) cells/mm3 at week 48. Eight patients experienced virologic failure, including 5 who developed rilpivirine resistance-associated mutations, mostly E138K, K101E and M230L. Mean (standard deviation) rilpivirine area-under-the-concentration-time curve from 0 to 24 hours (AUC24h and C0h) were 2391 (991) ng·h/mL and 83.5 (38.7) ng/mL, respectively. Conclusions: Rilpivirine safety, virologic and pharmacokinetic profiles were similar in treatment-naïve HIV-1-infected adolescents and adults, supporting use of rilpivirine 25 mg qd, plus other antiretrovirals, in treatment-naïve adolescents with VL ⩽100,000 copies/mL at treatment initiation.

[1]  L. Mofenson,et al.  Long-term Safety and Efficacy of Atazanavir-based Therapy in HIV-infected Infants, Children and Adolescents: The Pediatric AIDS Clinical Trials Group Protocol 1020A , 2015, The Pediatric infectious disease journal.

[2]  Patrick A Ryscavage,et al.  Contemporary issues on the epidemiology and antiretroviral adherence of HIV-infected adolescents in sub-Saharan Africa: a narrative review , 2015, Journal of the International AIDS Society.

[3]  C. Giaquinto,et al.  Efficacy and Safety of Darunavir/Ritonavir at 48 Weeks in Treatment-naïve, HIV-1–infected Adolescents: Results From a Phase 2 Open-label Trial (DIONE) , 2014, The Pediatric infectious disease journal.

[4]  Douglas J. Taylor,et al.  Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials , 2014, AIDS and Behavior.

[5]  V. van Eygen,et al.  96-Week Resistance Analyses of Rilpivirine in Treatment-Naive, HIV-1-Infected Adults from the Echo and Thrive Phase Iii Trials , 2013, Antiviral therapy.

[6]  H. Crauwels,et al.  Impact of Food and Different Meal Types on the Pharmacokinetics of Rilpivirine , 2013, Journal of clinical pharmacology.

[7]  M. Maskew,et al.  Treatment outcomes of HIV-infected adolescents attending public-sector HIV clinics across Gauteng and Mpumalanga, South Africa. , 2013, AIDS research and human retroviruses.

[8]  N. Clumeck,et al.  Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100 000 copies/ml or less: week 48 phase III analysis , 2013, AIDS.

[9]  H. Stellbrink,et al.  Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials , 2013, AIDS.

[10]  V. van Eygen,et al.  Pre-Existing Mutations in the Rilpivirine Phase Iii Trials Echo and Thrive: Prevalence and Impact on Virological Response , 2013, Antiviral therapy.

[11]  S. Macleod,et al.  Adherence to Antiretroviral Therapy in HIV-Positive Adolescents in Uganda Assessed by Multiple Methods , 2012, Pediatric Drugs.

[12]  S. Macleod,et al.  Adherence to Antiretroviral Therapy in HIV-Positive Adolescents in Uganda Assessed by Multiple Methods A Prospective Cohort Study , 2012 .

[13]  N. Rakhmanina,et al.  Pharmacotherapy of pediatric HIV infection. , 2012, Pediatric clinics of North America.

[14]  B. Clotet,et al.  Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients: Pooled Results From the Phase 3 Double-Blind Randomized ECHO and THRIVE Trials , 2012, Journal of acquired immune deficiency syndromes.

[15]  E. Deeks.  Atazanavir: in pediatric patients with HIV-1 infection. , 2012, Paediatric drugs.

[16]  S. Lawn,et al.  Treatment outcomes in HIV-infected adolescents attending a community-based antiretroviral therapy clinic in South Africa , 2012, BMC Infectious Diseases.

[17]  B. Clotet,et al.  Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE Studies: 48-Week Analysis , 2012, Journal of acquired immune deficiency syndromes.

[18]  Sylvie Naar-King,et al.  Barriers to Medication Adherence in Behaviorally and Perinatally Infected Youth Living with HIV , 2012, AIDS and Behavior.

[19]  S. Fidler,et al.  Optimizing antiretroviral therapy in adolescents with perinatally acquired HIV-1 infection , 2010, Expert review of anti-infective therapy.

[20]  P. Vis,et al.  Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral-naïve, HIV-1-infected patients in ECHO and THRIVE , 2010, Journal of the International AIDS Society.

[21]  D. Harris,et al.  Prevalence and interactions of patient-related risks for nonadherence to antiretroviral therapy among perinatally infected youth in the United States. , 2010, AIDS patient care and STDs.

[22]  Dirk Jochmans,et al.  TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1 , 2009, Antimicrobial Agents and Chemotherapy.

[23]  J. Ananworanich,et al.  Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children. , 2009, The Journal of antimicrobial chemotherapy.

[24]  D. Harris,et al.  Patient-related risks for nonadherence to antiretroviral therapy among HIV-infected youth in the United States: a study of prevalence and interactions. , 2009, AIDS patient care and STDs.

[25]  S. Reisner,et al.  A review of HIV antiretroviral adherence and intervention studies among HIV-infected youth. , 2009, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[26]  B. Chi,et al.  Simple adherence assessments to predict virologic failure among HIV-infected adults with discordant immunologic and clinical responses to antiretroviral therapy. , 2008, AIDS research and human retroviruses.

[27]  M. Hughes,et al.  Long-term Safety and Efficacy of a Once-Daily Regimen of Emtricitabine, Didanosine, and Efavirenz in HIV-Infected, Therapy-Naive Children and Adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021 , 2007, Pediatrics.

[28]  R. Chaisson,et al.  Adherence to Nonnucleoside Reverse Transcriptase InhibitorBased HIV Therapy and Virologic Outcomes , 2007, Annals of Internal Medicine.

[29]  Deenan Pillay,et al.  Update of the drug resistance mutations in HIV-1: Fall 2006. , 2006, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[30]  A. Walker,et al.  Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study , 2006, BMJ : British Medical Journal.

[31]  M. Sharland,et al.  PENTA guidelines for the use of antiretroviral therapy, 2004 , 2004, HIV medicine.

[32]  A. Moscicki,et al.  Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. , 2003, Archives of pediatrics & adolescent medicine.

[33]  Sue Eckstein,et al.  Clinical investigation of medicinal products in the paediatric population , 2003 .

[34]  E. Morse,et al.  Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. , 2002, Pediatrics.

[35]  G. Luftman,et al.  Antiretroviral adherence issues among HIV-positive adolescents and young adults. , 1999, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.